ISSN 1673-3770 CN 37-1437/R
Journal of Otolaryngology and Ophthalmology of Shandong University ›› 2023, Vol. 37 ›› Issue (5): 135-141.doi: 10.6040/j.issn.1673-3770.0.2022.214
• Review • Previous Articles Next Articles
TU Qiaoling1, LI Yufeng2, PENG Jun3
CLC Number:
| [1] 方三高, 魏建国, 周晓军. 解读WHO(2017)头颈部肿瘤分类(鼻腔、鼻窦、颅底)[J]. 诊断病理学杂志, 2018, 25(4): 241-245. doi:10.3969/j.issn.1007-8096.2018.04.001 [2] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi:10.3322/caac.21660 [3] Chang ET, Ye W, Zeng YX, et al. The evolving epidemiology of nasopharyngeal carcinoma[J]. Cancer Epidemiol Biomarkers Prev, 2021, 30(6): 1035-1047. doi:10.1158/1055-9965.EPI-20-1702 [4] Kuang-Rong Wei, Rong-Shou Zheng, Si-Wei Zhang, 等. 2013年中国鼻咽癌发病和死亡分析[J]. 癌症, 2018, 37(4): 170-178 [5] Chen YP, Chan ATC, Le QT, et al. Nasopharyngeal carcinoma[J]. Lancet, 2019, 394(10192): 64-80. doi:10.1016/S0140-6736(19)30956-0 [6] Perri F, Della Vittoria Scarpati G, Caponigro F, et al. Management of recurrent nasopharyngeal carcinoma: current perspectives[J]. Onco Targets Ther, 2019, 12: 1583-1591. doi:10.2147/OTT.S188148 [7] Lee AWM, Ng WT, Chan JYW, et al. Management of locally recurrent nasopharyngeal carcinoma[J]. Cancer Treat Rev, 2019, 79: 101890. doi:10.1016/j.ctrv.2019.101890 [8] Zhang Y, Chen L, Hu GQ, et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma[J]. N Engl J Med, 2019, 381(12): 1124-1135. doi:10.1056/NEJMoa1905287 [9] Lv JW, Li JY, Luo LN, et al. Comparative safety and efficacy of anti-PD-1 monotherapy, chemotherapy alone, and their combination therapy in advanced nasopharyngeal carcinoma: findings from recent advances in landmark trials[J]. J Immunother Cancer, 2019, 7(1): 159. doi:10.1186/s40425-019-0636-7 [10] Chow JC, Ngan RK, Cheung KM, et al. Immunotherapeutic approaches in nasopharyngeal carcinoma[J]. Expert Opin Biol Ther, 2019, 19(11): 1165-1172. doi:10.1080/14712598.2019.1650910 [11] Guo Z, Wang YH, Xu H, et al. LncRNA linc00312 suppresses radiotherapy resistance by targeting DNA-PKcs and impairing DNA damage repair in nasopharyngeal carcinoma[J]. Cell Death Dis, 2021, 12(1): 69. doi:10.1038/s41419-020-03302-2 [12] Hong X, Liu N, Liang Y, et al. Circular RNA CRIM1 functions as a ceRNA to promote nasopharyngeal carcinoma metastasis and docetaxel chemoresistance through upregulating FOXQ1[J]. Mol Cancer, 2020, 19(1): 33. doi:10.1186/s12943-020-01149-x [13] Blanchard P, Lee A, Marguet S, et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis[J]. Lancet Oncol, 2015, 16(6): 645-655. doi:10.1016/S1470-2045(15)70126-9 [14] Yang P, Zhou T, Chen X, et al. Efficacy, safety, and biomarker analysis of camrelizumab in previously treated recurrent or metastatic nasopharyngeal carcinoma(CAPTAIN study)[J]. J Immunother Cancer, 2021, 9(12): e003790. doi:10.1136/jitc-2021-003790 [15] Larbcharoensub N, Mahaprom K, Jiarpinitnun C, et al. Characterization of PD-L1 and PD-1 expression and CD8+ tumor-infiltrating lymphocyte in Epstein-Barr virus-associated nasopharyngeal carcinoma[J]. Am J Clin Oncol, 2018, 41(12): 1204-1210. doi:10.1097/COC.0000000000000449 [16] Lau KM, Cheng SH, Lo KW, et al. Increase in circulating Foxp3+CD4+CD25(high)regulatory T cells in nasopharyngeal carcinoma patients[J]. Br J Cancer, 2007, 96(4): 617-622. doi:10.1038/sj.bjc.6603580 [17] Ding L, Lu S, Li Y. Regulation of PD-1/PD-L1 pathway in cancer by noncoding RNAs[J]. Pathol Oncol Res, 2020, 26(2): 651-663. doi:10.1007/s12253-019-00735-9 [18] Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity[J]. Annu Rev Immunol, 2008, 26: 677-704. doi:10.1146/annurev.immunol.26.021607.090331 [19] Dong HD, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion[J]. Nat Med, 2002, 8(8): 793-800. doi:10.1038/nm730 [20] Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint[J]. Immunity, 2018, 48(3): 434-452. doi:10.1016/j.immuni.2018.03.014 [21] Zhao R, Song Y, Wang Y, et al. PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway[J]. Cell Prolif, 2019, 52(3): e12571. doi:10.1111/cpr.12571 [22] Piao W, Li L, Saxena V, et al. PD-L1 signaling selectively regulates T cell lymphatic transendothelial migration[J]. Nat Commun, 2022, 13(1): 2176. doi:10.1038/s41467-022-29930-0 [23] Wang YQ, Zhang Y, Jiang W, et al. Development and validation of an immune checkpoint-based signature to predict prognosis in nasopharyngeal carcinoma using computational pathology analysis[J]. J Immunother Cancer, 2019, 7(1): 298. doi:10.1186/s40425-019-0752-4 [24] Fang W, Yang Y, Ma Y, et al. Camrelizumab(SHR-1210)alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials[J]. Lancet Oncol, 2018, 19(10): 1338-1350. doi:10.1016/S1470-2045(18)30495-9 [25] Ma BBY, Lim WT, Goh BC, et al. Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the mayo clinic phase 2 consortium(NCI-9742)[J]. J Clin Oncol, 2018, 36(14): 1412-1418. doi:10.1200/JCO.2017.77.0388 [26] Even C, Wang HM, Li SH, et al. Phase II, randomized study of spartalizumab(PDR001), an anti-PD-1 antibody, versus chemotherapy in patients with recurrent/metastatic nasopharyngeal cancer[J]. Clin Cancer Res, 2021, 27(23): 6413-6423. doi:10.1158/1078-0432.CCR-21-0822 [27] Wang FH, Wei XL, Feng J, et al. Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial(POLARIS-02)[J]. J Clin Oncol, 2021, 39(7): 704-712. doi:10.1200/JCO.20.02712 [28] Makowska A, Meier S, Shen L, et al. Anti-PD-1 antibody increases NK cell cytotoxicity towards nasopharyngeal carcinoma cells in the context of chemotherapy-induced upregulation of PD-1 and PD-L1[J]. Cancer Immunol Immunother, 2021, 70(2): 323-336. doi:10.1007/s00262-020-02681-x [29] Yuan Y, Adam A, Zhao C, et al. Recent advancements in the mechanisms underlying resistance to PD-1/PD-L1 blockade immunotherapy[J]. Cancers(Basel), 2021, 13(4): 663. doi:10.3390/cancers13040663 [30] Zhang P, Wu W, Chen Q, et al. Non-coding RNAs and their integrated networks[J]. J Integr Bioinform, 2019, 16(3): 20190027. doi:10.1515/jib-2019-0027 [31] Mohr AM, Mott JL. Overview of microRNA biology[J]. Semin Liver Dis, 2015, 35(1): 3-11. doi:10.1055/s-0034-1397344 [32] Wu RS, Qiu EH, Zhu JJ, et al. miR-101 promotes nasopharyngeal carcinoma cell apoptosis through inhibiting Ras/Raf/MEK/ERK signaling pathway[J]. Eur Rev Med Pharmacol Sci, 2020, 24(16): 8240. doi:10.26355/eurrev_202008_22580 [33] Liu YL, Yang WH, Chen BY, et al. miR-29b suppresses proliferation and induces apoptosis of hepatocellular carcinoma ascites H22 cells via regulating TGF-β1 and p53 signaling pathway[J]. Int J Mol Med, 2021, 48(2): 157. doi:10.3892/ijmm.2021.4990 [34] Kooshkaki O, Rezaei Z, Rahmati M, et al. miR-144: a new possible therapeutic target and diagnostic/prognostic tool in cancers[J]. Int J Mol Sci, 2020, 21(7): E2578. doi:10.3390/ijms21072578 [35] Huang W, Song W, Jiang Y, et al. C-Myc-induced circ-NOTCH1 promotes aggressive phenotypes of nasopharyngeal carcinoma cells by regulating the miR-34c-5p/c-Myc axis[J]. Cell Biol Int, 2021, 45(7): 1436-1447. doi:10.1002/cbin.11582 [36] Chen M, Chen C, Luo H, et al. MicroRNA-296-5p inhibits cell metastasis and invasion in nasopharyngeal carcinoma by reversing transforming growth factor-β-induced epithelial-mesenchymal transition[J]. Cell Mol Biol Lett, 2020, 25(1): 49. doi:10.1186/s11658-020-00240-x [37] Han JB, Huang ML, Li F, et al. MiR-214 mediates cell proliferation and apoptosis of nasopharyngeal carcinoma through targeting both WWOX and PTEN[J]. Cancer Biother Radiopharm, 2020, 35(8): 615-625. doi:10.1089/cbr.2019.2978 [38] Ashrafizadeh M, Zarrabi A, Hushmandi K, et al. PD-1/PD-L1 axis regulation in cancer therapy: the role of long non-coding RNAs and microRNAs[J]. Life Sci, 2020, 256: 117899. doi:10.1016/j.lfs.2020.117899 [39] Zhang Y, Zhu R, Wang J, et al. Upregulation of lncRNA H19 promotes nasopharyngeal carcinoma proliferation and metastasis in let-7 dependent manner[J]. Artif Cells Nanomed Biotechnol, 2019, 47(1): 3854-3861. doi:10.1080/21691401.2019.1669618 [40] Zheng YJ, Zhao JY, Liang TS, et al. Long noncoding RNA SMAD5-AS1 acts as a microRNA-106a-5p sponge to promote epithelial mesenchymal transition in nasopharyngeal carcinoma[J]. FASEB J, 2019, 33(11): 12915-12928. doi:10.1096/fj.201900803R [41] Zhang W, Guo Q, Liu G, et al. NKILA represses nasopharyngeal carcinoma carcinogenesis and metastasis by NF-κB pathway inhibition[J]. PLoS Genet, 2019, 15(8): e1008325. doi:10.1371/journal.pgen.1008325 [42] Mo Y, Wang Y, Zhang S, et al. Circular RNA circRNF13 inhibits proliferation and metastasis of nasopharyngeal carcinoma via SUMO2[J]. Mol Cancer, 2021, 20(1): 112. doi:10.1186/s12943-021-01409-4 [43] Fan C, Qu H, Xiong F, et al. CircARHGAP12 promotes nasopharyngeal carcinoma migration and invasion via ezrin-mediated cytoskeletal remodeling[J]. Cancer Lett, 2021, 496: 41-56. doi:10.1016/j.canlet.2020.09.006 [44] Yu H, Zhang C, Li W, et al. Nano-coated si-SNHG14 regulated PD-L1 expression and decreased epithelial-mesenchymal transition in nasopharyngeal carcinoma cells[J]. J Biomed Nanotechnol, 2021, 17(10): 1993-2002. doi:10.1166/jbn.2021.3162 [45] Tang Y, He Y, Shi L, et al. Co-expression of AFAP1-AS1 and PD-1 predicts poor prognosis in nasopharyngeal carcinoma[J]. Oncotarget, 2017, 8(24): 39001-39011. doi:10.18632/oncotarget.16545 [46] Wang S, You H, Yu S. Long non-coding RNA HOXA-AS2 promotes the expression levels of hypoxia-inducible factor-1α and programmed death-ligand 1, and regulates nasopharyngeal carcinoma progression via miR-519[J]. Oncol Lett, 2020, 20(5): 245. doi:10.3892/ol.2020.12107 [47] Ge J, Wang J, Xiong F, et al. Epstein-Barr virus-encoded circular RNA CircBART2.2 promotes immune escape of nasopharyngeal carcinoma by regulating PD-L1[J]. Cancer Res, 2021, 81(19): 5074-5088. doi:10.1158/0008-5472.CAN-20-4321 [48] Wang J, Ge J, Wang Y, et al. EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1[J]. Nat Commun, 2022, 13(1): 866. doi:10.1038/s41467-022-28479-2 [49] Wu Q, Zhao Y, Sun Y, et al. miR-375 inhibits IFN-γ-induced programmed death 1 ligand 1 surface expression in head and neck squamous cell carcinoma cells by blocking JAK2/STAT1 signaling[J]. Oncol Rep, 2018, 39(3): 1461-1468. doi:10.3892/or.2018.6177 |
| [1] | ZHOU Yijing, ZOU Jianyin, YI Hongliang, WU Hongmin. Expression of TGFBI in head and neck squamous cell carcinoma and its clinical significance [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023, 37(5): 85-95. |
| [2] | TANG Huixin, LI Jingjing, ZOU Hong. Mechanism and clinical applications of subthreshold diode micropulse laser [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023, 37(3): 143-148. |
| [3] | LIU Jiayu, FAN Huiming, ZOU You, CHEN Shiming. Research progress on the application of artificial intelligence in the diagnosis and treatment of nasopharyngeal carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023, 37(2): 135-142. |
| [4] | AI Ziqin, LI Junzheng. Advances in immune vaccines for head and neck squamous cell carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023, 37(2): 143-150. |
| [5] | REN Jia, LÜ Dan, ZHANG Yin, SUN Jiali, MA Lan, ZHENG Yitao, YANG Jimin, YU Lingyu, LI Bo. Application of combining fiberoptic endoscopic evaluation of swallowing technology and swallowing quality of life scale in patients with dysphagia after chemoradiotherapy for nasopharyngeal carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(6): 83-88. |
| [6] | HUA Hongli, LI Song,TAO Zezhang. Research progress of artificial intelligence in the diagnosis and treatment of nasopharyngeal carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(2): 113-119. |
| [7] | PANG Chong, BIAN Sainan, ZHANG Bing, YIN Xu, LU Yingxia, YE Pengfei, WANG Zhan, ZHAO Jing, GAO Yan, GUAN Kai. Short-term effect of Dermatophagoides farinae specific sublingual immunotherapy for children with allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(1): 70-74. |
| [8] | LI Menghui, ZHI Lili, QI Kaiwen, WANG Shanshan, GAO Qian, BU Meiling,. Clinical research of subcutaneous immunotherapy on children with allergic asthma caused by dust mites and combined with mold allergen [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(1): 75-80. |
| [9] | ZHOU Yuxiang,MIAO Beiping, LU Yongtian. Treatment progress of endoscopic surgery for first diagnosed nasopharyngeal carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2021, 35(6): 108-112. |
| [10] | WANG Zhongwei, YANG Lin, GUO Ya, SUN Bin, WANG Yali, MA Xiulong, REN Hongtao, BAO Xing. Analysis of the relationship between miR-429 and miR-200C expression and prognosis in patients with nasopharyngeal carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2021, 35(3): 81-86. |
| [11] | TAN Yufang, YI Tianhua. Clinical characteristics and prognosis of sudden sensorineural hearing loss in post-irradiated nasopharyngeal carcinoma survivors: a report of 18 cases [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2021, 35(1): 35-39. |
| [12] | FAN Li, LI Yue, XU Ximing. Changes in and prognostic value of the inflammatory index before and after concurrent chemoradiotherapy for nasopharyngeal carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(6): 36-41. |
| [13] | The objective of this study was to analyze the effects and possible regulatory mechanisms that Notch receptors could have on cisplatin resistance, observed in nasopharyngeal carcinoma. MethodsWestern blot analysis was used for the detection of Notch receptor expression in nasopharyngeal carcinoma cells and cisplatin-resistant nasopharyngeal carcinoma cells(5-8F, 5-8F/CDDP). Flow cytometry was used to investigate how the combined treatment with 10 μM CDDP and different concentrations of γ-secretase inhibitor(DAPT)could affect apoptosis in 5-8F/CDDP cells. Flow cytometry was also used for the detection of cell cycle stages in DAPT-treated 5-8F / CDDP cells. Finally, western blotting was also used for the detection of drug resistance-related protein expression. All experiments were followed by statistical data analysis. ResultsWe observed significantly higher Notch1 and Notch4 receptor expression in 5-8F/CDDP cells than in 5-8F cells(P=0.003, P=0.004). Furthermore, we described that Notch signaling was inhibited by DAPT in 5-8F/CDDP cells, followed by a significant increase in the apoptosis rate and decrease in cell proliferation, induced by cisplatin in a dose-dependent manner(P<0.05). Moreover, after inhibiting the Notch signaling pathway in 5-8F/CDDP cells, DAPT treatment significantly decreased the expression of Cyclin E and CDK-2, proteins involved in cell cycle regulation, and contributed to blocking the cells in the G1/S phase(P<0.05). At the same time, the expression levels of both the EMT-related protein Slug and the DNA excision repair protein ERCC1 significantly decreased, while that of E-Cadherin was up-regulated. ConclusionUp-regulated expression of Notch1 and Notch4 receptors is associated with cisplatin resistance in nasopharyngeal carcinoma cells. The inactivation of the Notch signaling pathway might thus have the potential to enhance the efficiency of cisplatin chemotherapy in drug-resistant nasopharyngeal carcinoma cells by inhibiting EMT rather than blocking the G1/S cell cycle phase.. Cisplatin resistance in nasopharyngeal carcinoma cells is affected by Notch receptors through the regulation of epithelial-mesenchymal transition rather than cell cycle controlHAN Jibo, ZOU You, YANG Rui, TAO Zezhang Department of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei, ChinaAbstract:Objective〓 [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(4): 105-110. |
| [14] | QING Xiaoyan,XU Yiquan,LI Chao. Advances in molecular mechanisms of anaplastic thyroid cancer [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(3): 26-31. |
| [15] | CHEN Xuesong, FU Weiwei, LIU Jiangtao. The prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in intensity modulated radiation therapy for nasopharyngeal carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(1): 50-53. |
|
||